CD33 and acute myeloid leukemia: GTB3550, a first-in-class TriKE, was evaluated among a small group of patients with R/R AML, revealing reproducible NK cell activity in all patients and suggesting that TriKEs could be a promising alternative to CD33-targeted agents [74].